CardioVere®

Designed to be the next generation congestion measurement device to help manage your heart failure patients.

CardioVere® Seeks To Become The Heart Failure Vital Sign

In development to be the only handheld, non-invasive, non-contact device to support fluid management for heart failure patients.

Intended to quantify early signs of decompensation
Early research* indicates detection of non-clinical and clinical congestion
Aims to improve care plan effectiveness to intervene when needed
Designed to enable more effective telemedicine visits with the goal of providing an assessment of tissue congestion before it negatively impacts patient health

Supported by a future platform to track/visualize changes that can be integrated in current systems
In combination with other vital parameters, CardioVere has the potential to provide physicians with a more accurate patient picture to adjust treatment accordingly

*ChemImage internal on file
* Illustrations are for demonstration purposes only. CardioVere is not commercially available or approved by the FDA.

CardioVere leverages proven, patented molecular chemical imaging technology developed by ChemImage. The technology uses light, filters, and optics paired with our proprietary algorithms and software enabling the user to see the unseen.

6.2 M

adults in the U.S. have been diagnosed with Heart Failure

CardioVere is being developed with the intention to enable more precise monitoring options for patients.

46 %

growth rate in heart failure diagnosis with an estimated 8M people in the U.S. by 2030

Heart failure will continue to be a cost burden. CardioVere aims to provide patient fluid information, a key indicator of heart failure status.

1 in 4

heart failure patients will be readmitted to the hospital within 30 days of discharge

CardioVere is being developed with patients in mind. Our objective is to give patients the option to monitor their fluid status at home and automatically inform their provider.

$70B

is the projected annual cost of heart failure by 2030

“The CardioVere CardioVerfication Index” is a consistent digital measurement of patient edema levels under development which may support clinical decision making. If clinically effective, it may also reduce length of stay.

Source: https://hfsa.org/patient-hub/heart-failure-facts-information